FDA issues warning of severe joint pain relating to DPP-4 inhibitors
The FDA has issued a warning to healthcare providers and patients about concerns over severe and disabling joint pain associated with DPP-4 inhibitors following a search of the FDA adverse event reporting system and published literature. The warning extends to Januvia (sitagliptin, Merck), Onglyza (saxagliptin, AstraZeneca), Tradjenta (linagliptin, Boehringer Ingelheim + Eli Lilly) and Nesina/Vipidia (alogliptin, Takeda) and their various combinations, Glyxambyi (linagliptin + empagliflozin), Jentadueto (linagliptin + metformin), Janumet (sitagliptin + metformin), Kombliglyze/Komboglyze (sitagliptin + metformin), Kazano/Vipdomet (alogliptin + metformin) and Oseni/Incresync (alogliptin + pioglitazone). Labels for the affected drugs will be updated.
See the full FDA notice here.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins